Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema

MLA

Ruslan Grishanin, et al. “Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.” Journal of Ocular Pharmacology and Therapeutics, vol. 37, no. 3, Apr. 2021, pp. 181–90. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fe8ea00a7357a6657211a3a2218d39f2&authtype=sso&custid=ns315887.

APA

Ruslan Grishanin, Pallavi Sharma, Szilard Kiss, Mehdi Gasmi, Claire M. Gelfman, Judith Greengard, Julio Nieves, Aivan Nguyen, & Kristina Oresic Bender. (2021). Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 37(3), 181–190.

Chicago

Ruslan Grishanin, Pallavi Sharma, Szilard Kiss, Mehdi Gasmi, Claire M. Gelfman, Judith Greengard, Julio Nieves, Aivan Nguyen, and Kristina Oresic Bender. 2021. “Comprehensive Preclinical Assessment of ADVM-022, an Intravitreal Anti-VEGF Gene Therapy for the Treatment of Neovascular AMD and Diabetic Macular Edema.” Journal of Ocular Pharmacology and Therapeutics 37 (3): 181–90. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....fe8ea00a7357a6657211a3a2218d39f2&authtype=sso&custid=ns315887.